BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Protein kinase B (AKT; AKT1; PKB; PKBA); phosphoinositide 3-kinase (PI3K); BRISC and BRCA1 A complex member 1 (BABAM1)

June 25, 2015 7:00 AM UTC

Cell culture studies suggest that AKT and PI3K inhibitors could be used to sensitize breast cancers to doxorubicin and prevent AKT-mediated doxorubicin resistance. In human breast cancer cell lines, d...